When the Sentinel Node Vanishes: Hidden Warning Sign in Head and Neck Melanoma

For patients diagnosed with melanoma on the head or neck, one of the most important questions asked in the days after diagnosis is whether the cancer has begun to spread. The standard way to answer that question is a procedure called sentinel lymph node biopsy, in which surgeons identify and remove the very first lymph node or nodes that drain lymph fluid away from the tumour site. If melanoma cells have begun travelling through the lymphatic system, they are most likely to appear in that sentinel node first, making it an extraordinarily powerful predictor of prognosis and a cornerstone of modern cancer staging. But what happens when the sentinel node simply cannot be found on the preoperative scans that are supposed to locate it? A new seventeen-year study suggests that this failure of visualisation is far from a harmless technical glitch, and may instead be a warning sign in its own right.

The research, conducted by a team at The Christie NHS Foundation Trust in Manchester and published in BMC Cancer, examined 400 patients who underwent wide local excision surgery for head and neck melanoma. The investigators set out to determine how often sentinel lymph nodes fail to show up on preoperative imaging, which patients are most likely to experience this failure, and, crucially, what it means for their long-term outcomes. Their findings, drawn from one of the largest cohorts assembled to address this question, add a striking new dimension to the way clinicians may need to interpret a negative or inconclusive lymphatic map.

The technique at the heart of the study is lymphoscintigraphy, a nuclear medicine imaging method in which a small amount of radioactive tracer is injected near the site of the tumour. The tracer travels along the same lymphatic channels that melanoma cells would use if they were spreading, and a gamma camera captures its journey in real time. Surgeons can then see exactly which lymph node basin receives the drainage, and a complementary technique called SPECT-CT, which fuses functional tracer information with detailed anatomical imaging, sharpens the picture further. In melanoma on the trunk or limbs, this process succeeds in identifying a sentinel node in the vast majority of cases. The head and neck, however, is a notoriously difficult territory: the lymphatic drainage patterns there are more variable, more abbreviated, and less predictable than anywhere else in the body.

That anatomical complexity showed itself clearly in the data. Among the 400 patients reviewed, sentinel lymph node visualisation was absent in 35 patients, a prevalence of 8.8 percent. In other words, nearly one in eleven patients with head and neck melanoma arrived at surgery without any identifiable sentinel node on their preoperative imaging. For a staging procedure whose entire value depends on finding that first draining node, this is a substantial minority, and one that has historically lacked a clear interpretation. Clinicians have long debated whether non-visualisation simply reflects quirky anatomy, technical limitations of the imaging, or something more biologically meaningful about the tumour itself.

The most arresting finding of the study concerns what happened next to those 35 patients. Melanoma recurrence occurred in 11 of them, amounting to 31.4 percent of the non-visualisation group. While the study’s design, as a retrospective cohort, cannot prove that the failed imaging directly caused or predicted recurrence in an individual patient, the sheer scale of that recurrence rate transforms the way a blank lymphoscintigram should be read. A scan that shows no drainage at all is not merely an absence of information; it appears to carry information of its own, and that information points toward heightened risk.

The researchers also uncovered patterns in who was most likely to experience non-visualisation. Age emerged as a powerful factor: patients whose sentinel nodes could not be visualised were significantly older than those whose scans succeeded, with a median age of 76 years compared with 65 years among patients with successful visualisation, a difference that was highly statistically significant. This aligns with a broader biological understanding of how lymphatic systems change over a lifetime. Lymphatic vessels can become less efficient with age, and the tracer that would race through the vessels of a younger patient may move sluggishly or not at all through aged, fibrotic, or attenuated lymphatic channels. Age-related changes in skin and subcutaneous tissue, along with cumulative sun damage in the head and neck region, may compound the effect.

Perhaps the most technically intriguing result concerns the relationship between non-visualisation and the substaging of tumours. Melanomas are classified using the T category system, which reflects tumour thickness and ulceration, and within each T category, the suffix ‘a’ denotes tumours without ulceration while ‘b’ denotes ulcerated tumours. The study found that absent drainage was substage-dependent, occurring more frequently in ‘a’ than ‘b’ substages across all T categories, with an odds ratio of 2.98 and a p-value of 0.011. In practical terms, patients with non-ulcerated tumours were roughly three times more likely to show failed sentinel node visualisation than patients with ulcerated tumours of the same thickness category. This is a counterintuitive result at first glance, since ulceration is itself an adverse prognostic feature, but it suggests that the biological characteristics driving lymphatic tracer uptake are not simply the same as those driving aggressive tumour behaviour, and that the two phenomena can diverge in ways clinicians have not previously appreciated.

The study also found that non-visualisation varied according to the primary anatomical site of the melanoma within the head and neck. This is consistent with the well-documented idiosyncrasies of cranial lymphatics: drainage from the scalp may skip conventional neck basins entirely, lesions of the ear and temple can drain to parotid nodes that sit perilously close to the injection site and may be masked by tracer scatter, and midface lesions can send drainage to multiple, asymmetric basins. The researchers identified melanoma sites using photography as part of their methodology, allowing precise correlation between where the tumour sat and whether the lymphatic map succeeded or failed. For surgeons planning a biopsy, this site-dependent variability underscores that the head and neck cannot be treated as a single homogeneous region when it comes to lymphatic mapping.

What are the implications for practice? Sentinel lymph node biopsy remains a key staging tool in head and neck melanoma, and nothing in this study overturns its central role. But the findings suggest that a preoperative scan showing no visualisation should not be dismissed as a technical inconvenience or an uninformative result. Instead, it may warrant heightened surveillance, a lower threshold for serial imaging follow-up, and careful counselling of the patient about their apparently elevated recurrence risk. The association with older age adds a further layer, since elderly patients already face competing health considerations and may benefit from an honest, data-driven conversation about what a failed map means for their individual situation. The substage dependence, meanwhile, hints that future staging discussions may need to incorporate imaging success or failure as a variable in its own right.

There are, as with all retrospective work, limits to how far the conclusions can be pushed. The study reviewed pre-existing clinical data over seventeen years, and imaging protocols, surgical techniques, and follow-up regimens will have evolved across that span. The 8.8 percent prevalence and the 31.4 percent recurrence figure describe this cohort, and confirmation in independent, prospectively collected datasets would strengthen the case for changing clinical guidelines. Even so, the message that emerges is both simple and potentially consequential: in head and neck melanoma, the lymphatic map that fails to light up is not empty of meaning. It may be one of the quiet signals that a patient’s disease is more dangerous than it appears, and learning to read that silence could help clinicians intervene earlier for the patients who need it most.

Subject of Research: Preoperative sentinel lymph node non-visualisation and recurrence risk in head and neck melanoma

Article Title: Preoperative sentinel lymph node non-visualisation in head and neck melanoma: a 17-year retrospective cohort study

Article References: Chowdhury, M., Gajanan, A., Alothman, A., Kumar, H., Walukiewicz, J., & Gajanan, K. (2026). Preoperative sentinel lymph node non-visualisation in head and neck melanoma: a 17-year retrospective cohort study. BMC Cancer. https://doi.org/10.1186/s12885-026-17053-4

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17053-4

Keywords: melanoma, head and neck cancer, sentinel lymph node biopsy, lymphoscintigraphy, SPECT-CT, cancer staging, lymphatic mapping, melanoma recurrence, tumour ulceration, nuclear medicine, surgical oncology, retrospective cohort study